Coherus BioSciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everybody. I'm Chris Schott from JPMorgan. And it's my pleasure to be introducing Coherus today at the JPMorgan Healthcare Conference.
From the company, we have Denny Lanfear, the company's President and CEO. Looking forward to Denny's comments. But before that, I did want to remind everybody, this will be a 40-minute session. (Operator Instructions)
So with that, I'll turn it over to Denny for the presentation.
Thank you, Chris, and thank you once again for inviting Coherus to present at the annual JPMorgan conference. It's a pleasure to be here.
Let me first, of course, apprise you of the forward-looking statements on Page 2 and direct you to the company's SEC filings with respect to each of the company's products, CHS-1420, our Humira biosimilar, as well as UDENYCA, our product, and so on.
Now on Slide 3, I'll just summarize for you our agenda
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |